Morgan Stanley analyst Sean Laaman has maintained their bullish stance on JAZZ stock, giving a Buy rating on October 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Buy rating due to a combination of factors, including the anticipated impact of Jazz Pharmaceuticals’ oncology launches and the upcoming Phase 3 GEA data. The company has recently adjusted its revenue guidance, primarily due to competitive pressures, but the inclusion of Modeyso in the NCCN guidelines and ongoing trials are expected to bolster its market position.
Laaman also highlights the potential of Ziihera, with previous data showing promising long-term outcomes, leading to increased confidence in its commercial success. The analyst has adjusted the duration of therapy for Ziihera, which could result in higher revenue estimates. Additionally, Jazz’s acquisition of a PRV is expected to generate significant proceeds, further supporting the positive outlook. These factors contribute to the raised price target and the Buy recommendation.
According to TipRanks, Laaman is a 4-star analyst with an average return of 8.7% and a 61.81% success rate. Laaman covers the Healthcare sector, focusing on stocks such as Neurocrine, Jazz Pharmaceuticals, and BioMarin Pharmaceutical.
In another report released on October 9, Bank of America Securities also maintained a Buy rating on the stock with a $230.00 price target.